New blood test for ovarian cancer detection
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 35 years or older
- You have female reproductive organs (includes women, trans men, and non-binary people)
- You either have a suspicious ovarian mass and are scheduled for surgery, OR you are healthy with no cancer history
- You are able to understand and agree to take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
This trial tests a new blood-based test (OCS) that looks for tiny particles from tumor cells to watch for cancer returning after initial treatment. It is for women with ovarian cancer whose CA125 levels were normal before starting treatment.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
This trial checks whether a “liquid biopsy,” a blood test, can help doctors tell apart different causes of a suspicious pelvic/ovarian mass and help with early detection. It may help avoid uncertainty before surgery by adding test results from blood along with imaging and standard markers.
This study is testing a new blood test (called the EARLY panel) to see how well it can detect ovarian cancer in postmenopausal women aged 50–74. It aims to find out if the test is accurate and practical for routine screening.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.